New hope for tough lymphomas? early trial of GNC-038 underway
NCT ID NCT05627856
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 28 times
Summary
This early-phase study is testing an experimental drug called GNC-038 in people with certain lymphomas (NK/T-cell, AITL, and other non-Hodgkin lymphomas) that have returned or not responded to standard therapy. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Only 4 participants are enrolled so far, and the study is active but not recruiting new patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510120, China
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510050, China
Conditions
Explore the condition pages connected to this study.